Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data Portfolio News / By Karina Tin November 21, 2022 Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data Read More »
Escient Pharmaceuticals Initiates Phase 2 Pacific Study Evaluating EP547, an Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus Portfolio News / By Karina Tin November 17, 2022 Escient Pharmaceuticals Initiates Phase 2 Pacific Study Evaluating EP547, an Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus Read More »
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock Portfolio News / By Karina Tin November 17, 2022 RAPT Therapeutics Announces Pricing of Public Offering of Common Stock Read More »
Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires Portfolio News / By Karina Tin November 16, 2022 Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires Read More »
Casma Therapeutics Raises $46.0 M in Series C Funding Portfolio News / By Karina Tin November 15, 2022 Casma Therapeutics Raises $46.0 M in Series C Funding Read More »
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update Portfolio News / By Karina Tin November 14, 2022 Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update Read More »
Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in Portfolio News / By Karina Tin November 10, 2022 Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in Read More »
RAPT Therapeutics Reports Third Quarter 2022 Financial Results Portfolio News / By Karina Tin November 10, 2022 RAPT Therapeutics Reports Third Quarter 2022 Financial Results Read More »
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Portfolio News / By Karina Tin November 10, 2022 Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update Read More »
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies Portfolio News / By Karina Tin November 10, 2022 Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies Read More »
